SEC Form 4 · accession 0001179110-15-014694
Ocata Therapeutics, Inc. · OCAT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Lanza
Officer — Chief Scientific Officer
Period of report
Nov 10, 2015
Accepted (ET)
Nov 10, 2015 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001140098
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 10, 2015 | S | 15,000 | $8.25 | D | 216,509 | D | |
| Common StockF1 | Nov 10, 2015 | S | 10,000 | $8.36 | D | 206,509 | D | |
| Common StockF1 | Nov 10, 2015 | S | 10,000 | $8.36 | D | 196,509 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 Plan.